| Literature DB >> 30042819 |
Azam Salari1, Kathrin Thomay1, Jana Lentes1, Juliane Ebersold1, Maike Hagedorn1, Britta Skawran1, Claudia Davenport1, Axel Schambach2, Brigitte Schlegelberger1, Gudrun Göhring1.
Abstract
TP53 deficiencies characterize myeloid malignancies with a dismal prognosis. To unravel the pathomechanism of TP53 mutations in the development of myeloid malignancies, we analyzed the functional properties of TP53 conformational and contact mutations and TP53 loss in human CD34+ cells. We show for the first time that the analyzed conformational mutations lead to higher cell viability in human hematopoietic stem progenitor cells. In contrast to these conformational mutations, contact mutations interfered with efficient erythropoiesis. These findings show that not only the detection of a TP53 mutation is important, but also the specific mutation may play a role in malignant transformation and progression.Entities:
Keywords: MDS; TP53 mutation; erythropoiesis; haematopoiesis; hematopoietic stem cells (HSCs)
Year: 2018 PMID: 30042819 PMCID: PMC6057451 DOI: 10.18632/oncotarget.25581
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Prevalence of TP53 hotspot mutations in Myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML)
| Frequency in AML/MDS [%] | ||||
|---|---|---|---|---|
| IARC1 | Papaemmanuil | TP53 Handbook3 | Ohgami | |
| R248W | 1.62 | 2.04 | 6.03 | 1.10 |
| R175H | 4.76 | 7.14 | 2.59 | 3.30 |
| R273H | 2.70 | 3.06 | 4.30 | 0.00 |
| R249S | 0.22 | 0.00 | n/a | 0.00 |
1IARC p53 mutation database.
2Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England Journal of Medicine. 2016; 374:2209–21.
3Hjortsberg L, Rubio-Nevado JM, Hamroun D, Béroud C, Claustre M, Soussi T. The p53 Mutation handbook 2.0, available online; http://p53.free.fr.
4Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Modern Pathology. 2015; 28:706–14.
Figure 1Vector constructs and their influence on apoptosis of CD34+ cells
(A) Overview of the workflow. (B) Under stress conditions apoptosis rate of CD34+ cells transduced with shTP53 is significantly lower than in CD34+ cells transduced with shScr or in non-transduced cells. (C) Under stress conditions CD34+ cells over-expressing wtTP53 have significantly higher apoptosis rates in comparison to controls and to cells with TP53 mutations R175H, R248W and R249S. (*P < 0.05; **P < 0.01; ***P < 0.001).
Figure 2Influence of TP53 hotspot mutations on hematopoiesis in colony forming unit (CFU) assays
(A) CFU results of knockdown of TP53 by shRNA: knockdown of TP53 did not influence colony numbers of CD34+ cells as compared to shScr as a control. (B) CFU results of knockdown of cells transduced with wtTP53 or TP53 mutations. After irradiation there was a weaker reduction in cell colony numbers in CD34+ cells transduced with conformational mutations (R175H and R249S), whereas CD34+ cells transduced with contact mutations (R248W and R273H) did not differ from those transduced with wtTP53. (C) Erythropoiesis in CD34+ cells overexpressing wtTP53 or expressing the contact mutations R248W and R273H was significantly reduced as compared to CD34+ cells transduced with conformational mutations. (*P < 0.05; **P < 0.01; ***P < 0.001).